Strategic overview of personalised medicine
(2012) International Pharmaceutical Industry — Vol. 4, n° 2, p. 58-62 (2012)
Files
strategicoverviewpersonalisedmedicinethelleputtejune2012.pdf
Restricted Access - Adobe PDF
- 443.05 KB
Details
- Authors
- Abstract
- "Personalised medicine is not yet fully implemented in healthcare developments, though the concept is several years old. The reasons might be scientific, technological, financial, regulatory, and ethical. The switch to personalised medicine cannot be achieved by merely considering one of those aspects isolated from the others, because they are all interleaved. It takes a global strategic analysis to determine how the healthcare industry should address this challenge. In this article, we outline recent trends in this regard. One observation relates to data science - or the lack of it - in current practice. So far, two players have been working together: the biopharma industry, responsible for R&D, production and commercialisation of the treatments on one hand, and the in vitro diagnostic (IVD) industry, responsible for biological measurements production on the other. The latter are supposed to address the issues of the former. Our point is that there is a missing link: players who can extract useful knowledge from the information contained within the huge amounts of data produced, be it clinical, -omics, imaging, etc. But data scientists are traditionally not massively present in the healthcare business. The integration of this complementary component into the current landscape is in itself a challenge, but full of opportunities [...]"
- Affiliations
Citations
Helleputte, T. (2012). Strategic overview of personalised medicine. International Pharmaceutical Industry, 4(2), 58-62. https://hdl.handle.net/2078.5/254504 (Original work published 2012)